CVS Health Co. (NYSE:CVS) Shares Sold by Capital Analysts LLC

Capital Analysts LLC decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 95.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,862 shares of the pharmacy operator's stock after selling 74,866 shares during the period. Capital Analysts LLC's holdings in CVS Health were worth $173,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nebula Research & Development LLC raised its position in shares of CVS Health by 322.5% in the 4th quarter. Nebula Research & Development LLC now owns 75,021 shares of the pharmacy operator's stock worth $3,368,000 after purchasing an additional 57,263 shares during the last quarter. Empire Financial Management Company LLC grew its stake in shares of CVS Health by 10.0% during the 4th quarter. Empire Financial Management Company LLC now owns 5,241 shares of the pharmacy operator's stock valued at $235,000 after purchasing an additional 475 shares during the period. Guardian Wealth Management Inc. increased its holdings in CVS Health by 151,236.4% during the fourth quarter. Guardian Wealth Management Inc. now owns 16,647 shares of the pharmacy operator's stock valued at $747,000 after buying an additional 16,636 shares during the last quarter. Voya Investment Management LLC lifted its position in CVS Health by 331.2% during the fourth quarter. Voya Investment Management LLC now owns 2,872,542 shares of the pharmacy operator's stock valued at $128,948,000 after purchasing an additional 2,206,299 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of CVS Health by 2.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,192,774 shares of the pharmacy operator's stock valued at $53,544,000 after acquiring an additional 26,738 shares during the period. Institutional investors own 80.66% of the company's stock.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Barclays increased their price target on CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a research note on Friday. Argus set a $77.00 target price on shares of CVS Health in a report on Tuesday, February 18th. Truist Financial boosted their price objective on shares of CVS Health from $76.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, April 11th. Piper Sandler upped their target price on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. Finally, Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $73.00.

Insider Activity at CVS Health

In other news, Director Michael F. Mahoney acquired 30,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 1.22% of the stock is owned by insiders.

CVS Health Stock Down 2.8 %

Shares of CVS stock traded down $1.96 during trading hours on Friday, reaching $67.49. 14,303,584 shares of the company's stock were exchanged, compared to its average volume of 11,663,528. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The stock's 50 day moving average is $66.64 and its 200-day moving average is $58.87. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The company has a market cap of $85.09 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same period in the prior year, the company posted $1.31 EPS. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. Analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.94%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.